Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30871
Title: Does a History of Cancer Influence the Effectiveness of Statins on Outcomes After Stroke?
Austin Authors: Olaiya, Muideen T;Andrew, Nadine E;Dalli, Lachlan L;Ung, David;Kim, Joosup;Sundararajan, Vijaya;Cadilhac, Dominique A;Thrift, Amanda G;Nelson, Mark R;Churilov, Leonid ;Kilkenny, Monique F
Affiliation: Monash University, Clayton, VIC, Australia
National Centre for Healthy Ageing, Frankston, Australia
The Florey Institute of Neuroscience and Mental Health
La Trobe University, Bundoora VIC, Australia
Menzies Institute for Medical Research, Hobart TAS, Australia.
Issue Date: 2022
Date: 2022
Publication information: Stroke 2022; 53(10): 3202-3205
Abstract: Evidence is growing on anticancer effects of statins. We investigated whether the effectiveness of treatment with statins after ischemic stroke on mortality is influenced by a history of cancer. Analyses of 90-day survivors of ischemic stroke (2012-2016; 45 hospitals) using linked registry and administrative data. Dispense of statins within 90 days postdischarge was determined from pharmaceutical records. Participants were followed from 91 days postdischarge until death or June 30, 2018. History of cancer was determined from hospital data. Propensity score-adjusted Cox proportional hazards regression model was used to determine the association between being dispensed statins and survival. The influence of history of cancer on this association was assessed based on the concepts of (1) statistical interaction and (2) biological interaction using 3 indices: relative excess risk due to interaction>0, attributable proportion due to interaction >0, or synergy index >1. Among 9948 eligible participants (median age=72 years, 42% female), there were 1463 deaths. In adjusted analyses, there was no statistical interaction between being dispensed statins and history of cancer on mortality (P=0.156). However, being dispensed statins had a significant positive biological interaction with having a history of cancer on mortality: relative excess risk due to interaction, 2.80 (95% CI, 1.56-5.05), attributable proportion due to interaction, 0.45 (95% CI, 0.23-0.66), and synergy index, 2.14 (95% CI, 1.32-3.49). Treatment with statins after ischemic stroke may confer additional survival benefits for people who also have had cancer.
URI: https://ahro.austin.org.au/austinjspui/handle/1/30871
DOI: 10.1161/STROKEAHA.122.038829
ORCID: 0000-0002-4070-0533
0000-0002-4846-2840
0000-0003-1449-9132
0000-0002-7931-6387
0000-0001-8162-682X
0000-0001-8533-4170
0000-0001-9941-7161
0000-0002-9807-6606
Journal: Stroke
PubMed URL: 36065808
Type: Journal Article
Subjects: atherosclerosis
cancer
cholesterol
ischemic stroke
mortality
risk
Appears in Collections:Journal articles

Show full item record

Page view(s)

24
checked on Nov 5, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.